Results
|
361.
|
|
|
362.
|
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. [electronic resource] by
- Toichi, Eiko
- Torres, Gisela
- McCormick, Thomas S
- Chang, Timothy
- Mascelli, Mary Ann
- Kauffman, Catharine L
- Aria, Nancy
- Gottlieb, Alice B
- Everitt, Daniel E
- Frederick, Bart
- Pendley, Charles E
- Cooper, Kevin D
Producer: 20061027
In:
Journal of immunology (Baltimore, Md. : 1950) vol. 177
Availability: No items available.
|
|
363.
|
|
|
364.
|
Genetic variations of IL17F and IL23A show associations with Behçet's disease and Vogt-Koyanagi-Harada syndrome. [electronic resource] by
- Hou, Shengping
- Liao, Dan
- Zhang, Jun
- Fang, Jing
- Chen, Lu
- Qi, Jian
- Zhang, Qi
- Liu, Yunjia
- Bai, Lin
- Zhou, Yan
- Kijlstra, Aize
- Yang, Peizeng
Producer: 20150615
In:
Ophthalmology vol. 122
Availability: No items available.
|
|
365.
|
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. [electronic resource] by
- Gordon, Kenneth B
- Strober, Bruce
- Lebwohl, Mark
- Augustin, Matthias
- Blauvelt, Andrew
- Poulin, Yves
- Papp, Kim A
- Sofen, Howard
- Puig, Lluís
- Foley, Peter
- Ohtsuki, Mamitaro
- Flack, Mary
- Geng, Ziqian
- Gu, Yihua
- Valdes, Joaquin M
- Thompson, Elizabeth H Z
- Bachelez, Hervé
Producer: 20181023
In:
Lancet (London, England) vol. 392
Availability: No items available.
|
|
366.
|
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. [electronic resource] by
- Reich, K
- Rich, P
- Maari, C
- Bissonnette, R
- Leonardi, C
- Menter, A
- Igarashi, A
- Klekotka, P
- Patel, D
- Li, J
- Tuttle, J
- Morgan-Cox, M
- Edson-Heredia, E
- Friedrich, S
- Papp, K
Producer: 20200828
In:
The British journal of dermatology vol. 181
Availability: No items available.
|
|
367.
|
|
|
368.
|
|
|
369.
|
|
|
370.
|
|
|
371.
|
Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab. [electronic resource] by
- Visvanathan, Sudha
- Baum, Patrick
- Vinisko, Richard
- Schmid, Ramona
- Flack, Mary
- Lalovic, Bojan
- Kleiner, Oliver
- Fuentes-Duculan, Judilyn
- Garcet, Sandra
- Davis, Justin W
- Grebe, Kristie M
- Fine, Jay S
- Padula, Steven J
- Krueger, James G
Producer: 20200505
In:
The Journal of allergy and clinical immunology vol. 143
Availability: No items available.
|
|
372.
|
Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis. [electronic resource] by
- Khalilieh, Sauzanne
- Hussain, Azher
- Montgomery, Diana
- Levine, Vanessa
- Shaw, Peter M
- Bodrug, Inga
- Mekokishvili, Lally
- Bailey-Smith, Candice
- Glasgow, Xiaoli S
- Cheng, Amy
- Martinho, Monika
- Iwamoto, Marian
Producer: 20191011
In:
British journal of clinical pharmacology vol. 84
Availability: No items available.
|
|
373.
|
Colitis-Induced Th17 Cells Increase the Risk for Severe Subsequent Clostridium difficile Infection. [electronic resource] by
- Saleh, Mahmoud M
- Frisbee, Alyse L
- Leslie, Jhansi L
- Buonomo, Erica L
- Cowardin, Carrie A
- Ma, Jennie Z
- Simpson, Morgan E
- Scully, Kenneth W
- Abhyankar, Mayuresh M
- Petri, William A
Producer: 20191125
In:
Cell host & microbe vol. 25
Availability: No items available.
|
|
374.
|
|
|
375.
|
|
|
376.
|
|
|
377.
|
|
|
378.
|
|
|
379.
|
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. [electronic resource] by
- Baeten, Dominique
- Østergaard, Mikkel
- Wei, James Cheng-Chung
- Sieper, Joachim
- Järvinen, Pentti
- Tam, Lai-Shan
- Salvarani, Carlo
- Kim, Tae-Hwan
- Solinger, Alan
- Datsenko, Yakov
- Pamulapati, Chandrasena
- Visvanathan, Sudha
- Hall, David B
- Aslanyan, Stella
- Scholl, Paul
- Padula, Steven J
Producer: 20190809
In:
Annals of the rheumatic diseases vol. 77
Availability: No items available.
|
|
380.
|
|